FDA 510(k) and De Novo Pathway for Autonomous Medical Devices
by Nick Clark | Published April 25, 2026
FDA 510(k) and De Novo pathways establish premarket clearance frameworks for medical devices, with emerging adaptation for autonomous-medical-device operations. Governed actuation provides architectural substrate for emerging autonomous-medical-device approval.
510(k) and De Novo Frame
FDA 510(k) requires substantial-equivalence demonstration; De Novo provides framework for novel device classification. Both pathways increasingly engage emerging autonomous medical device operations.
Architecture Implications
Autonomous medical-device clearance requires structural defensibility for incident reconstruction, safety demonstration, and emerging post-market surveillance.
Architectural Mapping
Stage-gated commitment supports phase-decomposed safety case. Reversibility classification supports risk analysis. Composite admissibility supports multi-authority autonomous-medical operations.
FDA Trajectory
FDA emerging autonomous medical device pathway development and emerging FDA PCCP integration push toward structurally-supported architecture.
